Today's Rundown Roivant licenses Ligand diabetes drug, founds Metavant, as push into cardiometabolic diseases gathers pace Aptose signs $125M-plus BET inhibitor deal with Ohm Oncology Eisai, partner Purdue hit phase 3 goals in sleep drug trial Esperion’s LDL treatment hits the mark in phase 3 Cancer vaccine startup Oxford Vacmedix taps Asian syndicate for series A cash Moderna’s vaccines head steps down as multiple programs undergo phase 1: report Novartis becomes deeper Science 37 partner, as pair aim for 10-trial launch Special Report—FierceBiotech’s rotten tomatoes and ripening fruit 2017 Featured Story | | | Wednesday, March 7, 2018 Roivant Sciences has picked up the rights to Ligand Pharmaceuticals’ glucagon receptor antagonist LGD-6972. The midphase Type 2 diabetes candidate slots into the pipeline of Roivant’s newly minted cardiometabolic disease startup Metavant. |
|
|
Top Stories Wednesday, March 7, 2018 The partnership for Aptose's third drug candidate comes as the biotech looks set to have its two lead drugs in clinical testing in the coming months. Wednesday, March 7, 2018 Japanese pharma Eisai and biopharma Purdue have posted positive late-stage results from their partnered sleep drug lemborexant. Wednesday, March 7, 2018 A 12-week course of Esperion's bempedoic acid lowered patients' LDL cholesterol by 23%, compared to a 5% increase observed in patients who received placebo. Wednesday, March 7, 2018 A syndicate of South Korean and Chinese investors has powered Oxford Vacmedix (OVM) to a series A round. OVM will use the $12.5 million (£9 million) investment to take vaccines against cervical cancer and other solid tumors into the clinic. Wednesday, March 7, 2018 Giuseppe Ciaramella, the leader of Moderna Therapeutics’ infectious diseases business, has jumped to a stealth-mode biotech startup, leaving a long list of clinical programs behind, according to STAT. Wednesday, March 7, 2018 Big Pharma Novartis is teaming up with virtual clinical trial company Science 37 to boost the Swiss major’s ability to run “site-less” studies. Tuesday, March 6, 2018 We started the Rotten Tomatoes special feature last year to spotlight companies that haven't followed through on the tough ethical and scientific demands of the biotech industry. This year, we’re at it again with a bit of a twist: We included companies bruised in 2016 but revived in 2017. | This week's sponsor is cobra:bio. | | | 1ml Long Syringe Line Now Available
In response to customer demand, Cobra has invested in an expansion of capabilities for batches up to 20k units. Today ~80% of the market for high value, low volume biologicals utilises the 1ml long format. More... |
Resources Sponsored by: MK&A There’s no magic bullet to successful access but insights from patient advocates and industry experts can help shape future strategies. Learn how in this webinar. Sign up now! Sponsored by: Reprints Desk The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market? Presented by: Box and USDM Life Sciences Learn how biopharma and medical device companies can now collaborate on, manage and distribute regulated clinical, lab and manufacturing content in Box. That means all of your content is standardized on a single content repository that meets regulatory and compliance standards, so you can eliminate inefficient silos, enable seamless collaboration and accelerate the validation process. Sponsored by: RBC Wealth Management Employee stock option trading & administration, Restricted stock transactions (Rule 144), Affiliated trading plans (10b5-1), Directed share plans, Equity comp plan administration — private to public Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Approval, Manufacturing Quality & Regulation 2018 | Online BioBasics: Biotech for the Non-Scientist March 29-30, 2018 | Boston, MA MIXiii-Biomed 2018 May 15-17, 2018 | Tel-Aviv, Israel Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! | 